Lisinopril formulations

  • US 9,814,751 B2
  • Filed: 04/10/2017
  • Issued: 11/14/2017
  • Est. Priority Date: 10/30/2015
  • Status: Active Grant
First Claim
Patent Images

1. A stable oral liquid formulation, comprising:

  • (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof;

    (ii) a sweetener selected from the group consisting of xylitol, mannitol, sucralose, saccharin, and pharmaceutically acceptable salts thereof;

    (iii) a buffer comprising citric acid and sodium citrate;

    (iv) a preservative selected from the group consisting of sodium benzoate, benzoic acid, sorbic acid, methylparaben, propylparaben, and pharmaceutically acceptable salts thereof; and

    (v) water;

    provided that when the preservative is a paraben, then the sweetener is not xylitol or mannitol; and

    wherein the formulation is stable at about 25±



    C. for at least 6 months.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×